International Journal of Cardiology
Volume 129, Issue 3 , Pages 373-378 , 13 October 2008

Lack of decrease in plasma N-terminal pro-brain natriuretic peptide identifies acute heart failure patients with very poor outcome

Received 24 March 2007 ,Accepted 7 July 2007.

References 

  1. Cleland JG, Swedberg K, Follath F, et al. The EuroHeart Failure survey programme — a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J. 2003;24:442–463
  2. Adams KF, Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005;149:209–216
  3. Zannad F, Mebazaa A, Juilliere Y, et al. Clinical profile, contemporary management and one-year mortality in patients with severe acute heart failure syndromes: the EFICA study. Eur J Heart Fail. 2006;8:697–705
  4. Nieminen MS, Brutsaert D, Dickstein K, et al. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J. 2006;27:2725–2736
  5. Gheorghiade M, Abraham WT, Albert NM, et al. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA. 2006;296:2217–2226
  6. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347:161–167
  7. Mueller C, Scholer A, Laule-Kilian K, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med. 2004;350:647–654
  8. McClure SJ, Caruana L, Davie AP, Goldthorp S, McMurray JJ. Cohort study of plasma natriuretic peptide for identifying left ventricular systolic dysfunction in primary care. BMJ. 1998;317:516–519
  9. McDonagh TA, Robb SD, Murdoch DR, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet. 1998;351:9–13
  10. Cowie MR, Struthers AD, Wood Coats AJ, Thompson SG, Poole-Wilson PA, Sutton GC. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet. 1997;350:1347–1351
  11. Bettencourt P, Ferreira A, Dias P, et al. Predictors of prognosis in patients with stable mild to moderate heart failure. J Cardiac Fail. 2000;6:306–313
  12. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic paptide (N-BNP) concentrations. Lancet. 2000;355:1126–1130
  13. Nagagava O, Ogawa Y, Itoh H, Suga S, Komatsu Y, Kishimoto I. Rapid transcriptional activation and early mRNA turnover of BNP in cardiocyte hypertrophy: evidence for BNP as an “emergency” cardiac hormone against ventricular overload. J Clin Invest. 1995;96:1280–1287
  14. Hystad ME, Geiran OR, Attramadal H, et al. Regional cardiac expression and concentration of natriuretic peptides in patients with severe chronic heart failure. Acta Physiol Scand. 2001;171:395–403
  15. Hartmann F, Packer M, Coats AJ, et al. Nt-proBNP in severe chronic heart failure: rationale, design and preliminary results of the COPERNICUS Nt-proBNP substudy. Eur J Heart Fail. 2004;6:343–350
  16. Murdoch DR, McDonagh TA, Byrne J, et al. Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy. Am Heart J. 1999;138:1126–1132
  17. Cheng V, Kazanagra R, Garcia A, et al. A rapid bedside test for B-type natriuretic peptide predicts treatment outcomes in patients admitted for decompensated heart failure. A pilot study. J Am Coll Cardiol. 2001;37:386–391
  18. Gackowski A, Isnard R, Golmard JL, et al. Comparison of echocardiography and plasma B-type natriuretic peptide for monitoring the response to treatment in acute heart failure. Eur Heart J. 2004;25:1788–1796
  19. Bettencourt P, Azevedo A, Pimenta J, Frioes F, Ferreira S, Ferreira A. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation. 2004;110:2168–2174
  20. Verdiani V, Nozzoli C, Francesca B, et al. Pre-discharge B-type natriuretic peptide predicts early recurrence of decompensated heart failure in patients admitted to a general medical unit. Eur J Heart Fail. 2005;7:566–571
  21. Nieminen MS, Bohm M, Cowie MR, et al. The Task Force on Acute Heart Failure of the European Society of Cardiology: executive summary of the guidelines on the diagnosis and treatment of acute heart failure. Eur Heart J. 2005;26:384–416
  22. Nohria A, Lewis E, Stevenson LW. Medical management of advanced heart failure. JAMA. 2002;287:628–640
  23. Ishii J, Nomura M, Nakamura Y, et al. Risk stratification using a combination of cardiac troponin T and brain natriuretic peptide in patients hospitalized for worsening chronic heart failure. Am J Cardiol. 2002;89:691–695
  24. Januzzi JL, Camargo CA, Anwaruddin S, et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol. 2005;95:948–954
  25. Logeart D, Thabut G, Jourdain P, et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk or re-admission after decompensated heart failure. J Am Coll Cardiol. 2004;43:635–641
  26. O'Brien RJ, Squire IB, Demme B, Davies JE, Ng LL. Pre-discharge, but not admission, levels of NT-proBNP predict adverse prognosis following acute LVF. Eur J Heart Fail. 2003;5:499–506
  27. Januzzi JL, Kimmenade RV, Lainchbury J, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients. Eur Heart J. 2006;27:330–337
  28. Kubler P, Petruk-Kowalczyk J, Majda J, et al. Persistent high NTpro-BNP concentration as a negative prognostic factor in patients with decompensated heart failure. Kardiol Pol. 2006;64:250–256
  29. Anand IS, Fisher LD, Chiang YT, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation. 2003;107:1278–1283
  30. Jourdain P, Funck K, Gueffet P. Benefit of BNP plasma levels for optimizing therapy: the Systolic Heart Failure Treatment Supported by BNP Multicenter Randomized Trial (STARS-BNP) (Abstract). J Am Coll Cardiol. 2005;45:3A
  31. Hobbs RE. Using BNP to diagnose, manage and treat heart failure. Clev Clin J Med. 2003;70:303
  32. Wu AH, Smith A. Biological variations of the natriuretic peptides and their role in monitoring patients with heart failure. Eur J Heart Fail. 2004;6:355–358
  33. Hall C. Essential biochemistry and physiology of (NT-pro)BNP. Eur J Heart Fail. 2004;6:257–260
  34. Hunt PJ, Richards AM, Nicholls MG, Yandle TG, Doughty RN, Espiner EA. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. Clin Endocrinol. 1997;47:287–296

PII: S0167-5273(07)01713-5

doi: 10.1016/j.ijcard.2007.07.126

International Journal of Cardiology
Volume 129, Issue 3 , Pages 373-378 , 13 October 2008

Article Tools

* Image Usage & Resolution